SCO-101 combined with FOLFIRI in metastatic colorectal cancer
CORIST, phase II
The aim of the CORIST phase II study is to investigate SCO-101 in combination with FOLFIRI in patients with metastatic colorectal cancer (mCRC). Patients enrolled in the CORIST trial have failed all prior standard chemotherapy and have entered a terminal stage of their disease with little hope of either a cure or of extending life further.
CORIST part 1
The first part of the CORIST phase II study, which aimed at establishing a safe dose (maximum tolerated dose) of SCO-101 when given together with FOLFIRI was successfully completed in June 2021. SCO-101 was administered once daily on day 1 to day 6 and FOLFIRI was administered on day 5 to 7.
CORIST part 2
The ongoing second part of the CORIST phase II study only includes patients with RAS wild-type tumors, based on findings in CORIST part 1. Part 2 of the CORIST study continues the focus on safety, tolerability, and efficacy parameters, for SCO-101 on a schedule combining SCO-101 and FOLFIRI over 7 days.
Topline data from CORIST part 2 was presented in Q3, 2022.
CORIST part 3
In August 2022, Scandion Oncology received approvals for the next parts of the CORIST trial. CORIST part 3 represents an expansion of CORIST phase II, in order to best exploit SCO-101’s potential in mCRC.
The trial was expanded by adding a new schedule for combining SCO-101 and chemotherapy (FOLFIRI), which will be evaluated in patients with both RAS wild-type and RAS mutated tumors.
Patient recruitment in part 3 commenced in Q3, 2022, and topline results from CORIST part 3 are expected most likely within Q3, 2023.
SCO-101 combined with nab-paclitaxel and gemcitabine in pancreatic cancer
PANTAX, phase Ib
In the PANTAX study, patients with unresectable or metastatic pancreatic cancer receive SCO-101 treatment in combination with nab-paclitaxel and gemcitabine which is standard first- or second-line chemotherapy.
The aim of the ongoing phase Ib study is to establish a safe dose (maximum tolerated dose) of SCO-101 in combination with nab-paclitaxel and gemcitabine.
Read-out from the PANTAX phase Ib study is expected in the first half of 2023.